(Q44381875)

English

A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens

scientific article published on 28 March 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

nucleus accumbens

1 reference

based on heuristic

inferred from title

author name string

Zhu Li

1

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Junji Ichikawa

2

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Herbert Y Meltzer

3

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

publication date

28 March 2003

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

Psychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

167

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

315-323

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

https://scigraph.springernature.com/pub.10.1007/s00213-003-1418-x

0 references

Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

SR46349-B, a 5-HT(2A/2C) receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

Ziprasidone, a new atypical antipsychotic drug

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

3H-spiroperidol binding to dopamine receptors in rat striatal membranes: Influence of loxapine and its hydroxylated metabolites

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

Cholinergic modulation of basal and amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

The role of alpha2-adrenoceptor antagonism in the anti-cataleptic properties of the atypical neuroleptic agent, clozapine, in the rat

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

Do loxapine plus cyproheptadine make an atypical antipsychotic? PET analysis of their dopamine D2 and serotonin2 receptor occupancy

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

The D2 receptor occupancy profile of loxapine determined using PET.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

Risperidone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

Anti-dopaminergic and anti-muscarinic effects of dibenzodiazepines: relationship to drug induced Parkinsonism

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2c receptor

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

Potency of antipsychotics in reversing the effects of a hallucinogenic drug on locus coeruleus neurons correlates with 5-HT2 binding affinity.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

Attenuation of haloperidol-induced catalepsy by a 5-HT2C receptor antagonist

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

Postsynaptic 5-hydroxytryptamine(1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

A Clinical Guide to Antipsychotic Drugs

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

Comparison of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe cell firing and the role of 5-HT1A receptor activation

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

Increase of extracellular dopamine in the prefrontal cortex: a trait of drugs with antidepressant potential?

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

Antagonism by neuroleptics of serotonin 5-HT1A and 5-HT2 receptors of normal human brain in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy

1 reference

https://api.crossref.org/works/10.1007%2FS00213-003-1418-X

21 January 2018

Does loxapine have "atypical" properties? Clinical evidence

1 reference

https://pubmed.ncbi.nlm.nih.gov/12664192

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neuroleptic and non-neuroleptic catalepsy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12664192

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacologic features and effects of neuroleptics

1 reference

https://pubmed.ncbi.nlm.nih.gov/12664192

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

5-HT(1A) and 5-HT(2A) receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex

1 reference

https://pubmed.ncbi.nlm.nih.gov/12664192

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes

1 reference

https://pubmed.ncbi.nlm.nih.gov/12664192

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder

1 reference

https://pubmed.ncbi.nlm.nih.gov/12664192

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/12664192

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of acute schizophrenia with loxapine succinate (Loxitane) in a controlled study with chlorpromazine

1 reference

https://pubmed.ncbi.nlm.nih.gov/12664192

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Characterization of typical and atypical antipsychotic drugs based on in vivo occupancy of serotonin2 and dopamine2 receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/12664192

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Loxapine: Fifteen years’ clinical expenence

1 reference

https://pubmed.ncbi.nlm.nih.gov/12664192

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dopamine antagonism by thioridazine in schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/12664192

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/12664192

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low-dose loxapine in the treatment of schizophrenia: is it more effective and more "atypical" than standard-dose loxapine?

1 reference

https://pubmed.ncbi.nlm.nih.gov/12664192

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12664192

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values

1 reference

https://pubmed.ncbi.nlm.nih.gov/12664192

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dopamine2 receptor occupancy and the action of clozapine: does it make a difference to add a neuroleptic?

1 reference

https://pubmed.ncbi.nlm.nih.gov/12664192

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/12664192

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00213-003-1418-X

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44381875&oldid=2020650675"